Industry Overview of Oncolytic Virus Therapies Market

Oncolytic virus therapies revolutionize cancer treatment by utilizing viruses to selectively infect and eradicate cancer cells. These therapies employ a diverse range of both natural and genetically modified viruses, including herpes simplex, vaccinia, adenovirus, reovirus, picornavirus, and others. By infecting cancer cells, oncolytic viruses activate the immune system and effectively target solid tumors, melanoma, and unresectable lesions. Unlike conventional chemotherapy, these therapies specifically target tumor cells while sparing healthy cells, resulting in reduced toxicity. Oncolytic virus therapies have demonstrated superior efficacy and the potential to prolong the survival of cancer patients. As a result, they are widely implemented in hospitals, clinics, and cancer research institutes for various therapeutic applications.

How Big Is the Oncolytic Virus Therapies Market?

The global oncolytic virus therapies market size reached US$ 130.4 Million in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 492.6 Million by 2028 exhibiting a CAGR of 20.90% during 2023-2028.

Oncolytic Virus Therapies Market Trends and Drivers:

The oncolytic virus therapies market is witnessing substantial growth driven by the widespread adoption of these therapies for the treatment of various cancers, such as glioblastoma, breast, lung, and prostate. These therapies are highly valued for their potent anti-tumor properties and their ability to precisely target tumors while minimizing damage to healthy surrounding tissues. The increasing demand for oncolytic virus therapies in the management of melanomas, including hematological malignancies, lymphoma, leukemia, and myeloma, is further fueling market growth. Moreover, patients' growing concerns regarding the adverse effects associated with conventional cancer treatments like surgery, radiotherapy, chemotherapy, and immunotherapy are contributing to the expansion of the market. The market is also positively influenced by a growing number of clinical studies focusing on oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia, which have shown promising results in advanced stages of research. Furthermore, the demand for advanced treatments and novel therapeutics, coupled with government initiatives aimed at raising awareness about cancer causes and promoting early diagnosis, are expected to drive the oncolytic virus therapies market.

Global Oncolytic Virus Therapies Market 2023-2028 Analysis and Segmentation:

Top Key Players covered in this report are: Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad.

The report segmented the market based on region, digital channel and end-use industry.

Breakup by Virus Type:

• Genetically Engineered Oncolytic Viruses
  • Herpes Simplex Virus
  • Adenovirus
  • Vaccinia Virus
• Oncolytic Wild-Type Viruses
  • Reovirus
  • Newcastle Disease Virus
  • Vesicular Stomatitis Virus

Breakup by Application:

• Solid Tumors
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Glioblastoma
• Melanoma
  • Hematological Malignancies
  • Lymphoma
  • Leukemia
  • Myeloma 

Breakup by End Use:

• Hospitals
• Specialty Clinics
• Cancer Research Institute

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Key Highlights of the Report:

Market Performance (2017-2022)

Market Outlook (2023-2028)

Market Trends

Market Drivers and Success Factors

Impact of COVID-19

Value Chain Analysis

Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Media Contact:

Company Name: IMARC Group

Contact Person: Elena Anderson

Email: sales@imarcgroup.com

Phone: +1-631-791-1145

Address: 134 N 4th St

City: Brooklyn

State: NY

Country: United States

Website: https://www.imarcgroup.com